Biennial report on genitourinary cancers
The last 2 years (2014 and 2015) have witnessed major advances in the treatment of genitourinary malignancies. Of note and in marked contrast to previous years, all four major cancers (prostate cancer, testicular cancer, kidney cancer, and bladder cancer) have benefited from this progress. In prostate cancer, it was clearly demonstrated that a local treatment should be administered for high-risk localised disease. The standard of care was changed for patients with upfront metastatic disease with combined androgen deprivation therapy plus docetaxel becoming the new standard for fit patients with multiple bony metastases.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Karim Fizazi Tags: EJC Biennial Report Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Docetaxel | Kidney Cancer | Prostate Cancer | Taxotere | Testicular Cancer | Urology & Nephrology